Background: Among gynaecological cancers, ovarian malignancy is the most lethal, largely due to the fact that it is not diagnosed until late stage. Information concerning the frequency and pattern of ovarian tumours in Lagos is scant.
Objective: To present a 10 year retrospective histologic study of ovarian tumours in Lagos, Nigeria. The aim is to document the histologic pattern, prevalence and age distribution of ovarian tumours.
Method: The materials consisted slides, paraffin embedded tissue blocks, patients' case files and histology request forms of all ovarian biopsies received at the Morbid Anatomy department of Lagos University Teaching Hospital Idi-Araba, Lagos from 1991 to 2000.
Results: A total of 486 ovarian biopsies were studied out of which 203 specimens were true ovarian neoplasms. One hundred and sixty three (80.3%) of the true neoplasms were benign while malignant ovarian tumours constituted 40 (19.7%). Ovarian malignancy constituted about 7% of 203 gynaecological malignant tumours in the 10 year period under review. Tumours of germ cell origin were the commonest, accounting for 107 (52.7%) of the true ovarian neoplasm seen. Surface epithelial tumours constituted 56 (27.6%), while sex cord-stromal tumours contributed 32 (15.8%). Mature teratoma was the commonest benign tumour, accounting for 98 (60.1%) cases of benign ovarian tumours. It showed a wide age range of occurrence, with peak occurrence between 20 and 29 years. Serous cystadenocarcinoma (42.5%) was the commonest ovarian malignancy. Serous cystadenocarcinoma occurred between the ages of 20 and 69 years with highest frequency in 30-39 years age group,
Conclusion: The germ cell tumours were the commonest ovarian neoplasm followed by surface epithelial tumours. This pattern is seen in most parts of Nigeria and Africa.
Download full-text PDF |
Source |
---|
Sensors (Basel)
December 2024
Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.
Ovarian cancer (OC) must be detected in its early stages when the mortality rate is the lowest to provide patients with the best chance of survival. Lysophosphatidic acid (LPA) is a critical OC biomarker since its levels are elevated across all stages and increase with disease progression. This paper presents an LPA assay based on a thickness shear mode acoustic sensor with dissipation monitoring that involves a new thiol molecule 3-(2-mercaptoethanoxy)propanoic acid (HS-MEG-COOH).
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Department of Biotechnology and Genetic Engineering, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jedności 8, 41-200 Sosnowiec, Poland.
Ovarian cancer is one of the most prevalent cancers among women. Due to the frequent problems during treatment, such as relapses or the development of resistance to treatment, new methods of treating this disease are being sought. A special attention is directed towards the combination therapies combining several different anticancer agents.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.
Homologous recombination repair deficiency (HRD) is involved in the development of high-grade serous ovarian carcinoma (HGSOC) and its elevated sensitivity to platinum-based chemotherapy. To investigate the heterogeneity of the HRD-positive HGSOC we evaluated the HRD status, including BRCA mutations, genomic scar score, and methylation status of genes in 352 HGSOC specimens. We then divided the HRD-positive cohort into three molecular subgroups, the BRCA mutation cohort (BRCA+), BRCA1 methylation cohort (Meth+), and the rest of the HRD+ cohort (HRD+BRCA-Meth-), and evaluated their first-line chemotherapy response, benefit from olaparib, and progression-free survival (PFS).
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Department of Clinical Genetics, Odense University Hospital, 5000 Odense, Denmark.
Circulating tumor DNA (ctDNA) is a biomarker that could potentially improve the survival rate of ovarian cancer (OC), e.g., by monitoring treatment response and early relapse detection.
View Article and Find Full Text PDFLife (Basel)
December 2024
Molecular Oncology and Viral Pathology Group, Research Centre of IPO Porto (CI-IPOP), Pathology and Laboratory Medicine Department, Clinical Pathology SV/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto. CCC), 4200-072 Porto, Portugal.
Ovarian cancer (OC) presents daunting lethality rates worldwide, with frequent late-stage diagnosis and chemoresistance, highlighting the need for improved prognostic approaches. Venous thromboembolism (VTE), a major cancer mortality factor, is partially driven by endothelial dysfunction (ED). ED's pro-inflammatory state fosters tumour progression, suggesting a VTE-independent link between ED and cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!